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Diabetic wound regeneration using heparin-
mimetic peptide amphiphile gel in db/db mice†
Berna Senturk, a Burak M. Demircan,b Alper D. Ozkan,a Sehmus Tohumeken,a
Tuncay Delibasi,*c,d Mustafa O. Guler *a,e and Ayse B. Tekinay *a,b
There is an urgent need for more efficient treatment of chronic wounds in diabetic patients especially
with a high risk of leg amputation. Biomaterials capable of presenting extracellular matrix-mimetic signals
may assist in the recovery of diabetic wounds by creating a more conducive environment for blood vessel
formation and modulating the immune system. In a previous study, we showed that glycosaminoglycan-
mimetic peptide nanofibers are able to increase the rate of closure in STZ-induced diabetic rats by induc-
tion of angiogenesis. The present study investigates the effect of a heparin-mimetic peptide amphiphile
(PA) nanofiber gel on full-thickness excisional wounds in a db/db diabetic mouse model, with emphasis
on the ability of the PA nanofiber network to regulate angiogenesis and the expression of pro-inflamma-
tory cytokines. Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization,
enhance the deposition of collagen and expression of alpha-smooth muscle actin (α-SMA), and eliminate
the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in the diabetic
wound site. As the absence of neovascularization and overexpression of pro-inflammatory markers are a
hallmark of diabetes and interfere with wound recovery by preventing the healing process, the heparin-
mimetic PA treatment is a promising candidate for acceleration of diabetic wound healing by modulating
angiogenesis and local immune response.
1. Introduction
Diabetes mellitus is a multi-systemic chronic disease that is
associated with severe wound infections. Type 2 diabetes melli-
tus is the most common type of diabetes in humans and pre-
sents as hyperglycemia resulting from a combination of
insulin resistance and reduction in insulin secretion in later
stages.1 Both type 1 and type 2 diabetic patients suffer from
delayed wound healing and the potential progression of skin
wounds into diabetic ulcers, which affect roughly 5% of dia-
betic patients and remains a major concern for diabetes man-
agement.2 Biomaterials capable of enhancing the repair of dia-
betic wounds are, therefore, promising for improving the
quality-of-life of diabetic patients.3
Diabetic wounds are characterized by the low expression of
angiogenic growth factors, prolonged inflammation, impaired
cellular activity and relative lack of skin tissue remodeling.4,5
During wound healing, growth factors are released from a
broad variety of cells and provide the signals required for
wound closure. The reduced expression of angiogenic growth
factors, such as vascular endothelial growth factor (VEGF), is
strongly associated with the failure of angiogenesis.6
Angiogenesis is a critical aspect of wound healing since it pri-
marily facilitates the transfer of oxygen and nutrients to the
wound site during the proliferative and remodeling phases of
wound healing. The inhibition of angiogenesis therefore
imposes severe constraints to the metabolic resources that are
available at the site of injury, and may consequently prevent
wound closure in diabetic patients. Wound closure is further
delayed in diabetic mice due to the sustained expression of
pro-inflammatory cytokines such as interleukin 6 (IL-6) and
tumor necrosis factor-alpha (TNF-α) at the wound site.7 Non-
healing wounds are also characterized by the overexpression of
IL-6 and associated with skin pathologies such as psoriasis,
while chronic increments in the expression of TNF-α is associ-
ated with decreased collagen deposition and impaired wound
healing.8–10 On the other hand, IL-6 deficient (IL-6 KO) mice
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show severe impairments in wound healing compared to wild
type control animals, suggesting that inflammatory cytokines
also play a fundamental role in initiating the healing response.
Diabetic animal models are produced either by chemical
induction (most commonly with STZ) or through systemic
mutations such as obese/obese (ob/ob) and diabetes/diabetes
(db/db mice).11 Although chemically induced diabetes provides
a simple and relatively cheap diabetic model, there is some evi-
dence that it is not completely representative of diabetes in
humans.12 On the other hand, genetic models allow the investi-
gation of the natural mechanisms of diabetes without the
potential side effects associated with chemical treatment, and
obese models (ob/ob, db/db) of type 2 diabetes are especially
close to the human disease, as these animals naturally develop
hyperglycaemia as a consequence of obesity and exhibit many
of the symptoms observed in type 2 diabetic patients. In particu-
lar, the db/db mouse model is among the most popular models
of diabetes, and also causes obesity at the age of 4 weeks. These
mice become hyperinsulinemic at around the age of 2 weeks
and develop a resistance to insulin, eventually (4–8 weeks) exhi-
biting advanced hyperglycaemia due to beta cell failure.13 While
diabetes is also very severe in ob/ob mice, the underlying cause
of diabetes in this strain is a deficiency in leptin rather than
leptin receptors, and ob/ob mice do not exhibit complete beta
cell failure. As such, ob/ob mice are generally not considered to
be representative of human diabetes.11 Therefore, the db/db
mouse model was chosen to accurately reflect the pathophysiol-
ogy of diabetes and investigate whether heparin-mimetic PA
treatment is able to reduce the abnormalities in wound healing
normally seen in diabetic injuries.
Peptide amphiphile molecules have received considerable
attention in the recent decades due to their ability to present
bioactive signals without necessitating the production and iso-
lation of complex proteins from xenogenic sources. In
addition, the nanofibrous networks formed by PA assemblies
closely resemble the structure of the extracellular matrix and
allow PA molecules to effectively present their bioactive epi-
topes to their target cells. We had previously developed a PA-
based material that is able to enhance angiogenesis both
in vitro and in vivo by mimicking the inductive signals inherent
to heparin molecules.14 The bioactive PA nanofibers in particu-
lar exhibit a strong potential to accelerate the wound healing
process by protecting and improving the bioavailability of
various growth factors.15 Heparin PA treatment improved
wound healing in STZ-induced diabetic rats by induction of
neovascularization.16 In the current study, wound healing
capacity of a heparin-mimetic gel was analyzed in the db/db
diabetic wound model. Although modulation of monocyte/
macrophage number upon treatment was investigated in STZ-
induced rats, the effect of PA treatment on the inflammatory
phase was not clear.16 In this study, the anti-inflammatory
effect of the heparin mimetic gel was analyzed for the first
time by pro-inflammatory markers IL-6 and TNF-α.
Here, we demonstrate the effect of heparin-mimetic PA
nanofiber gels on the recovery of diabetic wounds by analyzing
the wound healing rate, re-epithelialization, granulation tissue
formation, blood vessel density and the inflammatory
response of full skin thickness wounds in db/db transgenic
mice. In addition, the effect of heparin-mimetic nanofibers on
the expression of VEGF and the pro-inflammatory cytokines
IL-6 and TNF-α was examined. The progression of wound
healing was compared between the bioactive gel treated and
PBS control diabetic mice. The efficacy of heparin-mimetic gel
treatment was evaluated and we show potential usage of the
heparin-mimetic gel on healing of chronic wounds.
2. Materials and methods
2.1. Materials
6 mm biopsy punches were purchased from Microtek Medical,
Zutphen NL. ELISA antibodies for IL-6 (14-7061) and TNF-α
(CMC3013) were purchased from eBioscience and Life
Technologies, respectively. Db/db transgenic mice were sup-
plied from Indiana, USA. All ELISA reagents were purchased
from Life Technologies. For peptide synthesis, 9-fluorenyl-
methoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) pro-
tected amino acids (except glyco-amino acid), [4-[α-(2′,4′-
dimethoxyphenyl)fmocaminomethyl]phenoxy]acetamidonor-
leucyl-MBHA resin (Rink amide MBHA resin) and 2-(1H-benzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU) were purchased from NovaBiochem. Methylene chlor-
ide (DCM), N,N-dimethylformamide (DMF) and trifluoroacetic
acid (TFA) solutions were purchased from Sigma Aldrich.
2.2. Peptide synthesis and self-assembled nanofibrous
network formation
Functionalized PA molecules were synthesized by standard
solid phase Fmoc peptide synthesis chemistry. For heparin-
mimetic PA synthesis, Lauryl-VVAGEGDK(pbs)S-Am (GAG-PA)
and Lauryl-VVAGK-Am (K-PA) were synthesized on Rink amide
resin. Amino acid coupling reactions were performed with
2 equivalents of Fmoc-protected amino acid, 1.95 equivalents
of HBTU, and 3 equivalents of DIEA for 4 h. The Fmoc protect-
ing group was removed with 20% piperidine/DMF solution for
20 min. Peptides were cleaved from the resin using 95 : 2.5 : 2.5
TFA/TIS/H2O for 3 h. Excess TFA was removed by rotary evapor-
ation. The remaining peptide was precipitated with ice-cold
diethyl ether and freeze-dried. The peptide was characterized
by quadruple-time-of-flight mass spectrometry (Q-TOF MS)
and purified with reverse phase preparative HPLC (Fig. S1†).
Nanofibers were formed by mixing negatively charged
GAG-PA and positively charged K-PA at pH 7.4 at a 1 : 2 ratio,
respectively. The net charge of the system is −1. It was pre-
viously shown that the negative charge of the peptide is critical
for the binding capacity of the heparin-mimetic nanofiber to
VEGF.14,15 Aqueous solutions of peptide amphiphiles were pre-
pared in double distilled water.
2.3. Transmission electron microscopy (TEM)
GAG-PA/K-PA peptide nanofibers were diluted from 10 mM
stock to 50 µM for TEM sample preparation. Peptide nano-
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fibers were placed on a TEM grid, incubated for 7 min and
stained with 2 wt% uranyl-acetate for 1 min. Imaging was per-
formed with a FEI Tecnai G2 F30 TEM at 200 kV.
2.4. Scanning electron microscopy (SEM)
A mixture of GAG-PA and E-PA was prepared on a silicon wafer
and incubated for 20 min for gelation. Peptide samples were
dehydrated through gradually increasing the concentrations of
ethanol solutions and completely dried in a critical point
dryer. The samples were coated with a 5 nm-thick Au–Pd layer
and imaged by using a FEI Quanta 200 FEG SEM, using the
GSED detector at an ESEM mode with 3–10 keV beam energy.
2.5. Circular dichroism analysis
Secondary structures of nanofibers were assessed by circular
dichroism (CD) analysis using a J-815 Jasco spectrophoto-
meter. 3.6 × 10−4 M aqueous solutions of peptide amphiphiles
were used for CD spectroscopy. Measurements were acquired
at room temperature with a 500 nm min−1 scanning speed,
1 nm bandwidth and 0.1 nm data pitch within the data inter-
val of 300 to 190 nm. Measurements were repeated three times
and averaged for each sample. The results were represented as
molar ellipticity.
2.6. Oscillatory rheology
Oscillatory rheology measurements were performed with an
Anton Paar Physica MCR301. 10 mM of GAG-PA and K-PA were
mixed in a 1 : 2 ratio as used in experiments. Rheological ana-
lyses were performed, angular frequency was kept constant at
10 rad s−1, and strain was increased between 0.1 and 100%.
Storage and loss moduli were recorded accordingly.
2.7. Animals and wound healing model
All animal experiments were performed on 12–16 week old,
genetically diabetic mice (db/db; BKS.Cg-+Leprdb/+Leprdb/
OlaHsd, USA, IN) in accordance with the guidelines set by the
Diskapi Hospital Animal Ethics Committee after obtaining
their official approval.
Mice were anesthetized with xylazine hydrochloride
(Alfazyne, 10 mg kg−1) and ketamine hydrochloride (Alfamine,
25 mg kg−1) and randomly divided into two cohorts as control
(n = 6) and GAG-PA/K-PA treated (n = 6) groups. Two full-thick-
ness circular wounds with 6 mm diameters were created on
each animal using disposable biopsy punches. One wound was
treated with GAG-PA/K-PA while the other one was treated with
PBS on the same animal (Fig. 2B). There is no side preference
for the treatment, the right side of the equal number of
animals was treated with GAG-PA/K-PA or PBS solution. All
wounded mice were housed individually. The wounding oper-
ation and postoperative treatments were performed by the
same researcher. Bioactive gels were applied topically to the
wound area at a volume of 300 µL and a concentration of 1%
(w/v). Similarly, control wounds were treated with 300 µL of
PBS solution. Both treatments were applied for 2 days. All
wounds were covered with Octacare non-woven wound dres-
sing (OCTAMED) to prevent the leakage of materials from the
wound site. Animals were sacrificed on days 7, 14 and 21 for
analysis.
2.8. Wound analysis
Mice were anesthetized with xylazine hydrochloride and keta-
mine hydrochloride prior to wound closure measurements.
The wounds were photographed (days 7, 14, 21) and replicated
on transparent tracing paper (by tracing the border of the
wound covered with epithelium) to calculate the percentage of
wound closure. The paper was then scanned and transferred
into cross-sectional paper, and wound sizes were analyzed
using ImageJ software.
2.9. Histological analysis
Removed skin tissues were fixed in 10% formaldehyde for
24 h, embedded in paraffin and sectioned in 5 µm increments.
Hematoxylin–eosin (H&E) staining was performed for the
determination of the wound healing progress in the wound
bed, and Masson’s trichrome staining was performed for col-
lagen deposition and granulation tissue analysis. Prior to both
stainings, paraffin was removed with xylene washing and
tissue sections were rehydrated through graded alcohols to dis-
tilled water. Rehydrated samples were either stained with H&E
or immersed in phosphomolybdic acid, aniline blue, acetic
acid and ethanol for Masson’s trichrome staining. H&E- and
Masson’s trichrome-stained tissue sections were visualized on
an up-right microscope (Zeiss Axio Scope A1).
The collagen content and organization were further investi-
gated with Picrosirius red. Picrosirius staining was performed
with a counterstaining of hematoxylin. Slides were incubated
in 0.1% Sirius red in saturated picric acid for 1 hour at room
temperature. They were then washed with acidified water, de-
hydrated through ethanol and xylene, and sealed with mount-
ing medium. Picrosirius red staining slides were imaged under
polarized-light microscopy (Zeiss Axio Imager.A2 m).
For quantification of percentage of granulation tissue per
total wound area, H&E stained tissue sections from each
wound were used. The whole granulation tissue area was
traced, measured with ImageJ and divided the total wound
area. To determine the percentage of re-epithelialization, the
length of the newly formed epithelium and the distance
between the original wound margins were measured using the
ImageJ software and following formula was used:
% re‐epithelialization ¼ ½length of new epithelium=
½distance between the original woundmargins  100
Measurement procedures were performed by two research-
ers blind to the study group.
2.10. Immunohistochemistry
Tissue sections were deparaffinized by heat, immersed in
xylene, rehydrated, and washed in distilled water. For antigen
retrieval, samples were treated with citrate buffer in a steamer
at 100 °C for 10–15 min. Endogenous peroxidase activity was
blocked by placing the sections in 3% hydrogen peroxide for
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10 min. Non-specific staining was blocked with normal goat
serum, and the sections were incubated overnight with the
monoclonal von Willebrand Factor antibody (rabbit, ab6994,
Abcam, 1 : 500) at 4 °C. After washing, a horse radish peroxi-
dase (HRP)-labeled secondary antibody (anti-rabbit, ab6721,
Abcam, 1 : 500) was applied for 1 h at room temperature, and
the samples were then treated with diaminobenzidine (DAB).
The number of blood vessels was counted from the wound
area with positive staining of von Willebrand Factor staining
for each section and quantified by two independent observers.
The ImageJ analysis system was used to calculate the number
of vessels in each field.
2.11. Protein isolation and western blotting
Skin samples were homogenized in the Trizol® reagent, and
the protein-containing supernatant was removed and stored at
−80 °C. Protein concentrations were determined using the
BCA Protein Assay Kit. Equal amounts of proteins per lane
(50 μg) were separated by 5–12% SDS-PAGE and transferred to
a polyvinylidene difluoride (PVDF) membrane. The membrane
was blocked with 5% non-fat milk in TBS-T at room tempera-
ture for 2 h and then incubated overnight with an anti-VEGF
antibody (ABS82, Millipore, 1 : 2000) or α-SMA antibody
(Millipore, 1 : 50 000) at 4 °C. After washing in TBS-T, the blots
were incubated with a HRP-coupled secondary antibody
(12–349, Millipore, goat anti-rabbit IgG; 1 : 2000). The bands
were visualized using the Clarity™ western ECL blotting sub-
strate. GAPDH (Millipore; 1 : 1000) was used as the internal
control and treated with the same protocol. Protein amounts
in each sample were quantified using ImageJ software.
2.12. ELISA
Pro-inflammatory cytokine concentrations in wound tissues
were measured at the end of the experiment by sandwich-
ELISA. Protein concentrations were determined using the BCA
Protein Assay Kit and 50 ng protein samples were used.
MaxiSorpTM plates (Thermo Scientific, NUNC) were coated
with IL-6 (1 : 1000) (14-7061-81) or TNF-α (1 : 500) (CMC3013)
primary antibodies through overnight incubation at 4 °C. On
the next day, plates were washed, dried by tapping, blocked
with 0.5% BSA (2 h) and incubated with isolated protein from
tissues (overnight incubation at 4 °C). On the following day,
the protein samples were consecutively labeled with a biotin-
labeled secondary antibody (2 h) and HRP-conjugated strepta-
vidin (1 h) at room temperature.
For the determination of both types of collagen (collagen I
and collagen III) concentrations, indirect-ELISA was per-
formed. Plates were coated with isolated protein from wound
tissues (overnight incubation at 4 °C). On the next day, plates
were washed, dried by tapping, blocked with 0.5% BSA (2 h)
and anti-collagen III (1 : 500) (ab7778) or anti-collagen I
(1 : 500) (ab6308) primary antibodies through overnight incu-
bation at 4 °C. Then, plates were washed 5 times with washing
buffer and dried by tapping between each consecutive step.
The HRP-conjugated anti-IgG antibody was used as a second-
ary antibody and incubated for 2 h. The TMB (3,3′,5,5′-tetra-
methylbenzidine) substrate was added at the last step and the
reaction was stopped after 30 min with 1.8 N H2SO4. Color for-
mation was measured by using a microplate reader
(Spectramax M5, Microplate reader) as absorbance at 450 nm
wavelength. In order to obtain exact absorbance values that are
attributable solely to dye color, the measured values were sub-
tracted from a reference value (at 650 nm). All treatments were
performed with at least three replicates and shown as mean ±
standard error of mean.
2.13. Statistical analysis
Statistical analyses were performed using GraphPad Prism
5. Data analysis was carried out using two tailed Student’s
t test with the raw data. Error bars indicate ± SEM (standard
error of mean).
3. Results and discussion
3.1. Characterization of self-assembled heparin-mimetic
peptide nanofibers
Heparin-mimetic peptide components; Lauryl-VVAGEGDK
(pbs)S-Am (GAG-PA) and Lauryl-VVAGK-Am (K-PA) molecules
were synthesized by Fmoc solid-phase peptide synthesis. As
shown in the chemical structure of peptide amphiphile mole-
cules, they carry a hydrophobic alkyl tail, β-sheet forming
sequences and a bioactive epitope group (Fig. 1A). The GAG-PA
molecule bears a strong negative charge (−3) due to its gluta-
mate, aspartate and p-sulfobenzoic acid-modified lysine resi-
dues. On the other hand, K-PA carries a positive charge of +1,
which is localized on the protonated amino group of the lysine
residue and allows the molecule to serve as a charge-screening
entity for the self-assembly of GAG-PA/K-PA.
GAG-PA/K-PA scaffolds were characterized with SEM, TEM
and CD analysis. Circular dichroism (CD) spectroscopy ana-
lysis of PAs showed that co-assembled systems were oriented
in a β-sheet conformation, presenting a negative peak signal at
220 nm and a positive peak signal at 202 nm (Fig. S2A†).
While the GAG-PA/K-PA mixture had a β-sheet structure, the
individual peptides exhibit a combination of weak β-sheets
and random coils due to charge repulsion between the individ-
ual peptide units. Structural properties of the PA nanofiber
system were further characterized by SEM (Fig. 1C) and TEM
imaging (Fig. 1D). The three-dimensional nanofibrous struc-
ture of PA nanofibers was found to be quite similar to the
natural ECM.17
Physical characteristics of the PA assembly matrix are criti-
cal for the material to remain at the wound site throughout
the recovery period and support cell growth while allowing for
cellular migration and recruitment. Mechanical properties of
the matrix were investigated with oscillatory rheology. Storage
(G′) and loss (G″) moduli were scanned from 100 to 0.1 rad s−1
of angular frequency and with a constant shear strain. The
GAG-PA/K-PA mixture was found to have a higher storage
modulus (G′) than loss modulus (G″), suggesting that the
peptide nanofibers form hydrogels at pH 7.4 (Fig. S2B†).
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Storage modulus results show that the stiffness of the gels was
around 7.5 kPa. The viscoelastic behaviors observed in PA
scaffolds are favorable, as they are similar to ECM
remodeling.18
3.2. GAG-PA/K-PA treatment accelerates wound closure
To evaluate the effect of heparin-mimetic peptide treatment on
the wound healing process, we first focus on wound closure in
db/db mice. The rate of wound closure was only compared
between the bioactive gel and PBS control treatment groups;
non-bioactive peptide gel control was not used in this study
since it did not show any effect on wound healing in the pre-
vious study.16 It has been previously shown that non-bioactive
control of GAG-PA/K-PA did not induce angiogenesis either
in vitro or in vivo.14,15 Since it did not show any positive effect
on the wound healing mechanism, the non-bioactive control
gel group was not used in this study in order to not increase
the number of animals. Two wounds of full-thickness on the
dorsal part of the animal were created by using 6 mm diameter
biopsy punches and one side was treated with GAG-PA/K-PA
and the other side was treated with PBS (Fig. 2B). We analyzed
the healing progress of diabetic wounds at different time
points throughout 21 days of GAG-PA/K-PA (bioactive gel) and
PBS treatment groups. Db/db mice from each group were sacri-
ficed on days 7, 14 and 21 post-treatment for clinical obser-
vation, histological and molecular analysis. Fig. 2A shows
sequential photographs of two treatment groups on days 7, 14
and 21, respectively. Representative pictures of wounds from
diabetic animals indicated that control animals carry scabs
even after 21 days of recovery, while bioactive gel treated
animals exhibited completely re-epithelialized wounds on day
21 (Fig. 2A). Wound area quantifications showed that
GAG-PA/K-PA treated mice showed significantly smaller
wounds compared to the PBS control group on days 7, 14 and
21 (Fig. 2C). The wound size was around 44.1% on day 21 in
the bioactive gel treated group, while it was 58.4% in the
control group. As such, the wound closure was not complete
after 21 days even for the GAG-PA/K-PA treated group, but the
wound sizes were significantly smaller than the control group.
H&E staining was performed on mouse skin sections to
further investigate the changes that occur during the re-epithe-
lialization, granulation tissue formation and tissue remodeling
phases (Fig. 3 and 4). Morphological changes on diabetic
wounds, such as crust formation (Cr), replacement of the
wound matrix (M) and granulation tissue (G) formation were
observed on days 7 and 14 in both groups (Fig. 3A). H&E
stained sections were analyzed to quantify granulation tissue
formation and re-epithelialization in a blinded manner.
Histological analysis of healing wounds in db/db diabetic mice
showed faster re-epithelialization following GAG-PA/K-PA treat-
Fig. 1 Chemical view and structural characterization of GAG-PA/K-PA. PAs have three regions; hydrophobic tail (lauric acid), β-sheet forming amino
acids (VVAG) and peptide epitopes, as seen in the chemical view (A). Mixing of positively and negatively charged PAs resulted in the formation of gels
at pH 7.4 (B). SEM (C) and TEM (D) images of GAG-PA/K-PA show peptide nanofiber networks. Scale bars are 1 µm in SEM and 0.1 µm in TEM
images.
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ment compared to control on day 7 (Fig. 3). Calculation of
granulation area per total wound area indicated that the for-
mation of granulation tissue is faster in the bioactive gel
treated group on day 7; however, granulation tissue formation
rates were similar in later days of wound healing (Fig. 3B)
(days 14 and 21). After twenty-one days of recovery, almost the
entire wound area was covered by granulation tissue,
suggesting that granulation had been successfully completed
in both groups (Fig. 3A and B).
Re-epithelialization, which is one of the main markers of
successful wound closure, was determined by the measure-
ment obtained from the histological analysis of epithelial
tissue. We demonstrated that percentage re-epithelialization
was markedly higher in bioactive gel (24.44%) treated mice
compared to control (15.25%) on day 7 (Fig. 3C). This result
further confirms that bioactive gel treatment promoted wound
healing by accelerating wound closure in the early phase of re-
epithelialization.
3.3. Collagen determination in wound area
The synthesis and deposition of collagen is essential for the
healthy wound healing process. At the beginning of the pro-
liferation phase, the collagen layer in the wound area mainly
includes two types of collagens; type I and type III. However,
collagen deposition–replacement of type III collagen with type
I occurs throughout the wound healing process, and newly de-
posited collagen is re-aligned at the remodeling phase in par-
ticular. Collagen alignment is not only critical for wound con-
traction, but also determines the severity of scar tissue for-
mation.19 Therefore, cross-sections of skin tissue were ana-
lyzed by Picrosirius red and Masson’s trichrome staining, and
ELISA to understand whether bioactive gel treatment promotes
collagen deposition.
The content and organization of collagens were examined
under polarized light with Picrosirius red staining (Fig. 4).
In this staining, because of the difference in their pattern of
physical aggregation and thickness of collagen fibers the
green color represents type III collagen, whereas red color is
an indicator of type I collagen.20 As the wound healing pro-
ceeds, the green color denotes thin fibers disappeared and
replaced with tightly packed red bundles of type I collagen.21
As seen in Fig. 4, in the early stage of wound healing
(on day 7) green color and red color were present in the
wound area (A, C), however red color became more
Fig. 2 Bioactive heparin-mimetic peptide nanofiber treatment accelerates the recovery of diabetic wounds. Representative pictures illustrate the
closure of wounds in GAG-PA/K-PA and PBS treated animals on days 0, 7, 14 and 21 (A). Two wounds (red and blue circle) were created by biopsy
punches at the dorsal skin of db/db mice on day 0 (B). Wound area measurement showed that skin wounds of animals treated with GAG-PA/K-PA
nanofibers close faster than control animals, exhibiting smaller average wound areas at days 7, 14 and 21 (C). Values are expressed as mean ± SEM,
(n = 6), *p < 0.05.
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dominant on day 14 (B, D) in both groups. The alignment of
collagen fibers was mostly parallel to the epidermis (con-
tinuous white line) in the upper layer (dashed white lines),
and reticulated in the dermis and hypodermis on day 14
(Fig. 4B and D). No difference was observed between the bio-
active gel and control groups in the sense of collagen
organization.
The collagen deposition was further assessed through
Masson’s trichrome staining, showing that the thickness of
the fibers increased with the proximity to the wound edge on
day 7 (Fig. 5A). The synthesis of type III collagen reaches
maxima around day 7 and then undergoes degradation by
matrix metalloproteinases (MMPs).22 As tissue matured, the
replacement of collagen type III (light blue) by collagen type I
(dark blue) was detected by Masson’s trichrome staining
(Fig. S3†). Furthermore, syntheses of type I and III collagens
were investigated with ELISA (Fig. 5B) to determine the quality
of the ECM deposition. Although the collagen I/III ratio
showed no significant differences on day 7, it was significantly
higher on day 14 after wounding in GAG-PA/K-PA treated mice
compared to control. Both Masson’s trichrome staining and
ELISA results revealed that the collagen type I/III ratio
increased over time in both groups. The type I and III collagen
ratio in normal skin is approximately 4 : 1.23 The collagen type
I/III ratio was higher and more closer to normal skin in the
bioactive treated group.
Fig. 3 Histological analysis of H&E stained tissue sections from db/db mice treated with GAG-PA/K-PA and PBS, and unwounded healthy controls.
Changes in tissue morphology, such as the formation of a wound crust (Cr), wound matrix (M) and granulation tissue (G) were investigated through-
out the recovery period (A). The rate of granulation tissue formation was evaluated by calculating the ratio of the granulation tissue compared to the
total wound area (B). In GAG-/PA-K-PA treated mice, re-epithelialization was faster on day 7 compared to PBS control (C). Arrows indicate original
wound edge (A). Images were taken with 5× magnification by using an up-right microscope. Values are expressed as mean ± SEM, (n = 6), *p < 0.05,
scale bars = 500 µm.
Fig. 4 The content and orientation of collagens in full-thickness diabetic wound samples treated with GAG-PA/K-PA (A–C) and PBS (D–F). Tissue
sections were stained with Picrosirius red in picric acid and photographed under cross-polarized light. Images were taken on day 7 (A, D), day 14 (B,
E) and day 21 (C, F). Dashed white lines represent orientation of collagens and continuous white lines track border of epidermis (E) on day 14 (B, E).
Original magnification is 100× and scale bars are 200 µm.
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3.4. Angiogenic response was accelerated with increased
number of vessels and VEGF expression in heparin-mimetic
gel-treated animals
A proper diabetic wound healing requires an angiogenic
response which leads to an increase in the number of blood
vessels and expression of VEGF at the site of injury.6 It has
been previously shown that heparin-mimetic PA nanofibers
trigger the induction of angiogenesis in the cornea and show
high binding affinity against VEGF165.
14,15 Here, we were
prompted to determine whether enhanced angiogenesis was
also present in diabetic wounds treated with this system. We
used von Willebrand Factor staining, one of the most widely
used endothelial cell markers for studying angiogenesis. Blood
vessel formation was compared between GAG-PA/K-PA and PBS
treatment groups by the immunohistochemical staining with
von Willebrand Factor and quantifications were performed
based on its positive staining (Fig. 6A). As seen in Fig. 6B, the
number of vessels per field was higher in the bioactive gel
treated group compared to the control group on days 7 and 14.
The number of blood vessels in GAG-PA/K-PA treated groups
was also higher than control groups on day 21 but the differ-
ence was not statistically significant. This result revealed exten-
sive neovascularization occurs in gel treated groups but not in
control groups on days 7 and 14, suggesting that the peptide
network is able to enhance wound healing by facilitating the
formation of new blood vessels.
Furthermore, the angiogenic response of diabetic wounds
was investigated through the western blot analysis of the VEGF
protein level (Fig. 6C and D). The treatment of GAG-PA/K-PA
significantly increased the VEGF levels on days 7 and 21.
Interestingly, the administration of GAG-PA/K-PA on the
wound site did not cause a significant difference on VEGF on
day 14. VEGF level analyses further confirmed the presence of
heightened angiogenic activity in diabetic wounds following
heparin-mimetic PA treatment. The VEGF level was markedly
elevated; around 3.5-fold higher in the bioactive gel treated
group on day 7. This result is also consistent with the histo-
logical analysis of GAG-PA/K-PA treated wound tissue sections,
which had a highly proliferative healing profile, especially on
day 7.
3.5. α-SMA expression increases with bioactive gel treatment
The expression of α-SMA is a marker for the transition of fibro-
blast cells to myofibroblasts, which is essential for promoting
wound contraction in tissue injury.24 Besides myofibroblasts,
α-SMA is expressed by pericytes, which are required for the
maturation of blood vessels.25 As such, α-SMA expression is an
important marker for wound contraction and blood vessel
maturation on wounds.
Immunohistochemical staining of wound tissue sections
showed that the expression of α-SMA was higher in the bio-
active gel treated group on day 14 compared to control (Fig. 7A
and B). Furthermore, western blot analysis was performed for
quantification of α-SMA expression in tissue samples, and con-
firmed our α-SMA immunohistochemical staining results
(Fig. 7C and D). Similar to immunohistochemical analysis,
protein levels of α-SMA increased two-fold following bioactive
gel treatment compared to PBS control on day 14 (Fig. 7D).
Fig. 5 Masson’s trichrome staining of wounds (A) and quantification of the collagen I/III ratio in both groups (B). The staining indicates that granula-
tion tissue formation, re-epithelialization and cell infiltration occur in both groups, but are faster in the bioactive gel treated group on day 14. Data
are presented as means ± SEM, *p < 0.05, scale bars = 500 µm.
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However, α-SMA protein levels were very low and no change
was observed between the groups at day 7, suggesting that the
wounds were not mature enough to exhibit extensive α-SMA
expression at this stage. On day 21, the wounds in all groups
show increased expression of α-SMA, while a large (but statisti-
cally non-significant) difference was observed between the
groups. Immunohistochemical staining for α-SMA also
revealed extensive staining of blood vessel walls in the
GAG-PA/K-PA treated wounds, suggesting that the VEGF level
is upregulated in mice treated with the bioactive gel group.
Increased α-SMA expression by myofibroblasts and pericytes
enhanced wound contraction and granulation tissue matu-
ration in the heparin-mimetic gel treated group on day 14.
Myofibroblasts are largely responsible for wound contraction
and produce extracellular matrix components such as type I
and III collagens. The elevated α-SMA expression on day 14 is
also correlated with ELISA results of the collagen I/III ratio in
the bioactive gel treated group.
3.6. Heparin mimetic gel treatment affects wound
inflammatory response
Characterization of an inflammatory response of db/db mice
was performed by the ELISA analysis of two pro-inflammatory
cytokines; IL-6 and TNF-α as shown in Fig. 8. IL-6 is a cytokine
Fig. 6 Angiogenic response of diabetic wounds from GAG-PA/K-PA and PBS treated mice. Immunohistochemical staining for von Willebrand
Factor (vWF) (A) and quantification based on vWF staining (B) of the wound areas showed that number of blood vessels in bioactive gel treatment
was higher than control on days 7 and 14. Arrows indicate blood vessels (brown color) (A). Representative bands of GAG-PA/K-PA and control from
western blot analysis of VEGF are shown in (C). VEGF level was quantified using western blot bands and normalized to GAPDH (D). Data are pre-
sented as means ± SEM, *p < 0.05, **p < 0.01.
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that is strongly expressed in cutaneous wounds, and although
it was not statistically significant, its expression in db/db
wounds was found to increase following the application of
heparin-mimetic PA gels to the wound site (on day 7). A signifi-
cantly lower expression of the pro-inflammatory cytokine IL-6
was found in PA-treated wounds when compared with control
at days 14 and 21 (Fig. 8A). There was a marked decrease of
IL-6 expression in bioactive gel treated wounds compared to
their PBS-control treated counterparts (4.5-fold on day 14 and
2.5-fold on day 21), suggesting that the inflammatory response
is prolonged in PBS treated animals. Additionally, the
expression level of IL-6 in bioactive gel treated animals was
close to that of unwounded db/db mice at these time points.
The expression of TNF-α was also found to exhibit a similar
pattern as IL-6, with a significantly higher expression in both
control and GAG-PA/K-PA-treated animals on day 7, which sub-
sequently decreased on days 14 and 21 in the bioactive gel
group but not in the PBS-treated group (Fig. 8B). These results
suggest that treatment with GAG-PA/K-PA peptide nanofibers
initially upregulates the expression of the pro-inflammatory
cytokines IL-6 and TNF-α, but cytokine expression is then
downregulated to mediate the transit from the inflammatory
phase to the proliferative phase of wound healing.
While pro-inflammatory markers are strongly expressed in
recently inflicted wounds and serve to recruit and activate
macrophages and leukocytes at the site of injury,26 their pres-
ence must gradually diminish for the healing process to con-
tinue. As such, a balance between pro-inflammatory and anti-
inflammatory factors is necessary to stimulate the proliferation
of native cells at the wound site following the initial recruit-
ment of immune cells and the removal of cellular debris. In
db/db mice; however, a strong IL-6 and TNF-α presence is
observed at both early and later stages of wound healing,
leading to the sustained presence of pro-inflammatory macro-
phages and the impairment of the recovery process.27 Our
ELISA analyses suggest that IL-6 and TNF-α expressions are
high in both heparin-mimetic PA-treated and control groups at
day 7, but rapidly decrease in the bioactive gel treated group by
day 14 to a level comparable to unwounded skin. In contrast,
immunoregulatory markers are still strongly present at the
wound site at days 14 and 21 for the control group, suggesting
that GAG-PA/K-PA (but not PBS) is able to modulate the
immune response at the site of injury.
Fig. 7 α-SMA expression increased in the wound area of bioactive gel treated samples. Alpha-SMA staining (brown) of tissue sections treated with
GAG-PA/KP-A (A) and PBS control (B) on day 14, with hematoxylin counterstaining of nuclei (blue). The quantification of α-SMA was based on
western blot analysis and normalized to GAPDH (C, D). Significance levels were set at: *p < 0.05, scale bars = 200 µm.
Fig. 8 Expression of the pro-inflammatory cytokines IL-6 (A) and TNF-
α (B) in wound tissues on days 7, 14 and 21 and healthy (unwounded)
controls. IL-6 and TNF-α levels were measured by ELISA. Significance
levels were set at: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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This study demonstrates that heparin-mimetic PA nanofibers
were able to induce angiogenesis and accelerate wound healing
in genetically diabetic db/db mice. The application of a bio-
active gel to the wound site was found to accelerate wound
closure, re-epithelialization, myofibroblast activation and blood
vessel formation. It has been previously shown that heparin-
mimetic PAs provide an environment that leads to the slow
release of angiogenic growth factors, and especially VEGF.
Molecular analysis of GAG-PA/K-PA treated wound tissues
showed that the VEGF level was high even after 21 days follow-
ing wounding. The remarkable increase in the VEGF level,
together with positive α-SMA staining and extensive blood
vessel formation at the wound site, suggests that angiogenesis
is effectively induced by GAG-PA/K-PA in diabetic wounds. In
addition, the expression of pro-inflammatory markers IL-6 and
TNF-α initially increases and subsequently decreases in
GAG-PA/K-PA treated rats. A marked decrease in the expression
of both markers is a strong evidence of improved transition
between the inflammatory and proliferative phases in heparin-
mimetic gel treated animals. The results of this study indicate a
potential use of heparin-mimetic peptide nanofibers for the
treatment of diabetic wounds exhibiting impaired regeneration.
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